UBS raised the firm’s price target on Applied Therapeutics to $12 from $4 and keeps a Buy rating on the shares following the company’s FY23 report as the firm is expecting “continued success.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLT:
- Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
- Applied Therapeutics to sell 12.3M shares at $7.00 in private placement
- Applied Therapeutics Announces $100 Million Private Placement
- Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics receives FDA acceptance, Priority Review for govorestat NDA
